Blueprint Medicines Netherlands
This sponsor has funded 1 studies across 3 countries.
| EU PAS ID | Status | Title | Protocol uploaded | Results uploaded |
|---|---|---|---|---|
| 41969 | Planned | Observational study evaluating the long-term safety and efficacy of avapritinib in the first-line treatment of patients with platelet-derived growth... | No | No |
PAS by Risk Management Plan (RMP) requirement
Blueprint Medicines Netherlands
The RMP for a medical product outlines strategies to identify, assess, and mitigate risks, including PAS for further evaluation.
Category 1 studies are imposed as condition of marketing authorisation.
Category 2 studies are imposed as specific obligation of marketing authorisation.
Category 3 studies are required under other circumstances.
PAS by study status
Blueprint Medicines Netherlands
The study status is defined according to the timeline dates specified.
Planned studies have not collected any data yet.
Ongoing studies collect data and should publish protocols as soon as possible.
Finalised studies should publish results in the first two weeks after finalisation.
Countries
Blueprint Medicines Netherlands
3 Study countries specified are the following:
- Netherlands
- Spain
- United States